Table 3. Comparative analysis of each drug and associated pulmonary adverse drug events (ADEs) based on the new classification from different graphical least absolute shrinkage and selection operator (GLASSO) (GL) Clusters.
| Drug | Drug class | ADEs for EB05 > 1 (n) * | GL Cluster |
|---|---|---|---|
| Macitentan | AHAs | 1–15,17 (16) | 1 |
| Bosentan | AHAs | 1,2,4–15 (14) | 1 |
| Epoprostenol | ATAs | 1,2,4–9,11,12,15 (11) | 1 |
| Selexipag | ATAs | 2,4–12 (10) | 1 |
| Sildenafil | UAs | 1,2,4–12 (10) | 1 |
| Tadalafil | UAs | 1,2,4–12 (10) | 1 |
| Beraprost | ATAs | 1,2,5–9 (7) | 1 |
| Nifedipine | CCBs | 1–3,15,16 (5) | 2 |
| Candesartan | ARBs | 1,3,14,16 (4) | 2 |
| Althiazide\Spironolactone | COMBs | 4,10,11 (3) | 3 |
| Rilmenidine | AHAs | 4,10 (2) | 3 |
| Bisoprolol | BBAs | 1,2,14 (3) | 4 |
| Lercanidipine | CCBs | 1,14 (2) | 4 |
| Imidapril | ACEs | 1–3 (3) | 5 |
| Azelnidipine | CCBs | 1,3 (2) | 5 |
| Azilsartan Kamedoxomil | ARBs | 1,3 (2) | 5 |
| Benidipine | CCBs | 1,2 (2) | 5 |
| Cilnidipine | CCBs | 1,2 (2) | 5 |
| Telmisartan | ARBs | 1,3 (2) | 5 |
| Bendroflumethiazide | TDAs | 3,13 (2) | 6 |
| Doxazosin | AHAs | 3,13 (2) | 6 |
| Nicardipine | CCBs | 3,13 (2) | 6 |
*Below ADEs can be found corresponding to each drug:.
1. Parenchymal lung disorders NEC.
2. Pneumothorax and pleural effusions NEC.
3. Lower respiratory tract inflammatory and immunologic conditions.
4. Respiratory tract disorders NEC.
5. Breathing abnormalities.
6. Lower respiratory tract signs and symptoms.
7. Pulmonary oedemas.
8. Respiratory failures (Excl Neonatal).
9. Vascular pulmonary disorders NEC.
10. Bronchospasm and obstruction.
11. Coughing and associated symptoms.
12. Respiratory syncytial viral infections.
13. Bronchial conditions NEC.
14. Pulmonary thrombotic and embolic conditions.
15. Lower respiratory tract infections NEC.
16. Fungal lower respiratory tract infections.
17. Pleural infections and inflammations.